arachidonyltrifluoromethane and Melanoma

arachidonyltrifluoromethane has been researched along with Melanoma* in 1 studies

Other Studies

1 other study(ies) available for arachidonyltrifluoromethane and Melanoma

Article	Year
Nanoliposomal delivery of cytosolic phospholipase A Nanomedicine : nanotechnology, biology, and medicine, 2018, Volume: 14, Issue:3 Drug resistance and toxicity are major limitations of cancer treatment and frequently occurs during melanoma therapy. Nanotechnology can decrease drug resistance by improving drug delivery, with limited toxicity. This study details the development of nanoparticles containing arachidonyl trifluoromethyl ketone (ATK), a cytosolic phospholipase A Topics: Animals; Arachidonic Acids; Cell Proliferation; Drug Delivery Systems; Female; Humans; Liposomes; Melanoma; Mice; Mice, Nude; Nanoparticles; Phospholipase A2 Inhibitors; Phospholipases A2, Cytosolic; Tumor Cells, Cultured	2018

Article

Year

Nanoliposomal delivery of cytosolic phospholipase A

Nanomedicine : nanotechnology, biology, and medicine, 2018, Volume: 14, Issue:3

Drug resistance and toxicity are major limitations of cancer treatment and frequently occurs during melanoma therapy. Nanotechnology can decrease drug resistance by improving drug delivery, with limited toxicity. This study details the development of nanoparticles containing arachidonyl trifluoromethyl ketone (ATK), a cytosolic phospholipase A

Topics: Animals; Arachidonic Acids; Cell Proliferation; Drug Delivery Systems; Female; Humans; Liposomes; Melanoma; Mice; Mice, Nude; Nanoparticles; Phospholipase A2 Inhibitors; Phospholipases A2, Cytosolic; Tumor Cells, Cultured

2018